385 related articles for article (PubMed ID: 36935752)
1. Overview of the structure and function of the dopamine transporter and its protein interactions.
Nepal B; Das S; Reith ME; Kortagere S
Front Physiol; 2023; 14():1150355. PubMed ID: 36935752
[TBL] [Abstract][Full Text] [Related]
2. Allosteric modulation of serotonin and dopamine transporters: New insights from computations and experiments.
Nguyen H; Cheng MH; Lee JY; Aggarwal S; Mortensen OV; Bahar I
Curr Res Physiol; 2024; 7():100125. PubMed ID: 38836245
[TBL] [Abstract][Full Text] [Related]
3. The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter.
Shan J; Javitch JA; Shi L; Weinstein H
PLoS One; 2011 Jan; 6(1):e16350. PubMed ID: 21298009
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter.
Swant J; Goodwin JS; North A; Ali AA; Gamble-George J; Chirwa S; Khoshbouei H
J Biol Chem; 2011 Dec; 286(51):43933-43943. PubMed ID: 21990355
[TBL] [Abstract][Full Text] [Related]
5. Designing modulators of monoamine transporters using virtual screening techniques.
Mortensen OV; Kortagere S
Front Pharmacol; 2015; 6():223. PubMed ID: 26483692
[TBL] [Abstract][Full Text] [Related]
6. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity.
Miller GM; Yatin SM; De La Garza R; Goulet M; Madras BK
Brain Res Mol Brain Res; 2001 Feb; 87(1):124-43. PubMed ID: 11223167
[TBL] [Abstract][Full Text] [Related]
7. Impact of disruption of secondary binding site S2 on dopamine transporter function.
Zhen J; Reith ME
J Neurochem; 2016 Sep; 138(5):694-9. PubMed ID: 27315582
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer.
Gedeon PC; Indarte M; Surratt CK; Madura JD
Proteins; 2010 Mar; 78(4):797-811. PubMed ID: 19899168
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template.
Indarte M; Madura JD; Surratt CK
Proteins; 2008 Feb; 70(3):1033-46. PubMed ID: 17847094
[TBL] [Abstract][Full Text] [Related]
10. Cell-type-specific expression of catecholamine transporters in the rat brain.
Lorang D; Amara SG; Simerly RB
J Neurosci; 1994 Aug; 14(8):4903-14. PubMed ID: 8046459
[TBL] [Abstract][Full Text] [Related]
11. Dual Action of Zn2+ on the Transport Cycle of the Dopamine Transporter.
Li Y; Hasenhuetl PS; Schicker K; Sitte HH; Freissmuth M; Sandtner W
J Biol Chem; 2015 Dec; 290(52):31069-76. PubMed ID: 26504078
[TBL] [Abstract][Full Text] [Related]
12. Direct coupling of oligomerization and oligomerization-driven endocytosis of the dopamine transporter to its conformational mechanics and activity.
Sorkina T; Cheng MH; Bagalkot TR; Wallace C; Watkins SC; Bahar I; Sorkin A
J Biol Chem; 2021; 296():100430. PubMed ID: 33610553
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein.
Chang MY; Lee SH; Kim JH; Lee KH; Kim YS; Son H; Lee YS
J Neurochem; 2001 May; 77(3):754-61. PubMed ID: 11331404
[TBL] [Abstract][Full Text] [Related]
14. [
Strauss M; O'Donovan B; Ma Y; Xiao Z; Lin S; Bardo MT; Ortinski PI; McLaughlin JP; Zhu J
J Pharmacol Exp Ther; 2020 Aug; 374(2):241-251. PubMed ID: 32461322
[TBL] [Abstract][Full Text] [Related]
15. Allosteric Modulator KM822 Attenuates Behavioral Actions of Amphetamine in
Refai O; Aggarwal S; Cheng MH; Gichi Z; Salvino JM; Bahar I; Blakely RD; Mortensen OV
Mol Pharmacol; 2022 Mar; 101(3):123-131. PubMed ID: 34906999
[TBL] [Abstract][Full Text] [Related]
16. Insights from molecular dynamics: the binding site of cocaine in the dopamine transporter and permeation pathways of substrates in the leucine and dopamine transporters.
Merchant BA; Madura JD
J Mol Graph Model; 2012 Sep; 38():1-12. PubMed ID: 23079638
[TBL] [Abstract][Full Text] [Related]
17. Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat.
Adeniran C; Yuan Y; Davis SE; Lin C; Xu J; Zhu J; Zhan CG
ACS Chem Neurosci; 2021 May; 12(9):1519-1527. PubMed ID: 33886267
[TBL] [Abstract][Full Text] [Related]
18. Interrogating the Molecular Basis for Substrate Recognition in Serotonin and Dopamine Transporters with High-Affinity Substrate-Based Bivalent Ligands.
Andersen J; Ladefoged LK; Kristensen TN; Munro L; Grouleff J; Stuhr-Hansen N; Kristensen AS; Schiøtt B; Strømgaard K
ACS Chem Neurosci; 2016 Oct; 7(10):1406-1417. PubMed ID: 27425420
[TBL] [Abstract][Full Text] [Related]
19. Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport.
Quizon PM; Yuan Y; Zhu Y; Zhou Y; Strauss MJ; Sun WL; Zhan CG; Zhu J
J Neuroimmune Pharmacol; 2021 Dec; 16(4):854-869. PubMed ID: 33537927
[TBL] [Abstract][Full Text] [Related]
20. Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter.
Andersen J; Ringsted KB; Bang-Andersen B; Strømgaard K; Kristensen AS
Sci Rep; 2015 Oct; 5():15650. PubMed ID: 26503701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
